Single-dose Brazilian dengue vaccine hits almost 80 percent efficacy

A dengue vaccine being developed by the Butantan Institute, a major research facility owned by the São Paulo state government and the largest vaccine manufacturer in Latin America, had an efficacy of 79.6 percent in clinical trials, according to results published Thursday in The New England Journal of Medicine. Butantan conducted a three-year clinical trial
The post Single-dose Brazilian dengue vaccine hits almost 80 percent efficacy appeared first on The Brazilian Report.